Bardin Hill Management Partners LP Has $7.10 Million Holdings in Axonics, Inc. (NASDAQ:AXNX)

Bardin Hill Management Partners LP cut its position in Axonics, Inc. (NASDAQ:AXNX) by 2.4% in the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 105,545 shares of the company’s stock after selling 2,593 shares during the period. Axonics makes up about 2.9% of Bardin Hill Management Partners LP’s investment portfolio, making the stock its 7th largest position. Bardin Hill Management Partners LP’s holdings in Axonics were worth $7,096,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Alpine Associates Management Inc. boosted its holdings in shares of Axonics by 16.2% during the second quarter. Alpine Associates Management Inc. now owns 2,108,871 shares of the company’s stock worth $141,779,000 after acquiring an additional 294,100 shares during the period. Magnetar Financial LLC raised its position in Axonics by 218.3% during the first quarter. Magnetar Financial LLC now owns 1,146,019 shares of the company’s stock valued at $79,041,000 after purchasing an additional 785,981 shares in the last quarter. KRYGER CAPITAL Ltd acquired a new stake in shares of Axonics in the 1st quarter valued at $65,211,000. Wasatch Advisors LP raised its holdings in shares of Axonics by 0.7% during the 4th quarter. Wasatch Advisors LP now owns 704,521 shares of the company’s stock worth $43,842,000 after buying an additional 5,046 shares in the last quarter. Finally, Goldman Sachs Group Inc. increased its position in Axonics by 6.9% during the 4th quarter. Goldman Sachs Group Inc. now owns 621,570 shares of the company’s stock worth $38,680,000 after purchasing an additional 40,306 shares in the last quarter. 99.48% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Needham & Company LLC reaffirmed a “hold” rating on shares of Axonics in a research note on Monday, August 5th. Eight research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $69.57.

Axonics Trading Down 0.3 %

Shares of AXNX stock opened at $69.41 on Wednesday. The stock has a market cap of $3.54 billion, a price-to-earnings ratio of -216.91 and a beta of 0.81. The stock has a 50-day moving average of $68.85 and a 200-day moving average of $68.02. Axonics, Inc. has a 1-year low of $48.30 and a 1-year high of $69.91.

Axonics (NASDAQ:AXNX) last announced its quarterly earnings data on Thursday, August 1st. The company reported $0.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.10 by $0.03. The company had revenue of $114.57 million for the quarter, compared to the consensus estimate of $112.83 million. Axonics had a negative return on equity of 0.27% and a negative net margin of 0.42%. The firm’s revenue was up 23.3% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.15) EPS. Sell-side analysts forecast that Axonics, Inc. will post 0.24 earnings per share for the current year.

About Axonics

Axonics, Inc, a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI.